America allows resumption of vaccination with "Johnson & Johnson" vaccine

On Friday, the US health authorities allowed the resumption of vaccination operations in the United States with the "Johnson & Johnson" vaccine against Covid-19, in a decision that comes 10 days after the suspension of the use of this vaccine following the registration of rare cases of blood clots.

The US Centers for Disease Control and Prevention, the primary agency responsible for public health in the United States, and the FDA, said in a joint statement that “the use of the Janssen vaccine against Covid-19 should be resumed in the United States.” Considering that the benefits of the vaccine far outweigh its risks for adults.

Blood clots


The health authorities in the United States suspended on April 13 the vaccination operations with the giant American pharmaceutical company vaccine to clear the way for an investigation into the reasons that made a number of women who received this vaccine develop dangerous blood clots linked to a decrease in platelet levels.

And while the two agencies affirmed in their statement that they are “confident that this vaccine is safe and effective in preventing Covid-19,” they stressed that “at the present time, the available data indicate that the risk of developing a“ blood clot ”is very low, but FDA and CDD are very low. They will remain vigilant and will continue to investigate this danger. "

The statement pointed out that the Janssen vaccine information sheet has been updated so that it includes an indication of the risk of stroke in a very small number of people who receive this vaccine.

The decision of the US health authorities came shortly after a recommendation in this direction was issued by a committee of experts that met at the request of the US Centers for Disease Control and Prevention.

"Johnson & Johnson" scientific director, Paul Stoffels, said he was "grateful" for the experts ’recommendation that it was" an essential step for continuing in a safe environment the much-needed vaccinations of millions of people. "

And 7.98 million Americans had received the "Johnson & Johnson" vaccine before the decision was made to suspend vaccination with it.

One dose


and the "Johnson & Johnson" vaccine, which is especially distinguished by its single dose, obtained at the end of February a license from the US Medicines Agency as part of the emergency mechanism for vaccines.

According to data provided Friday, out of the 3.99 million women who received this vaccine in the United States, 15 women developed dangerous blood clots, and three of them died.

The vast majority of these women (13 out of 15) are under the age of 50, while the remaining two women are between 50 and 64 years old.

No man had a similar case of clotting.

On Friday, experts highlighted the many benefits offered by this single-dose vaccine, which can be stored in household refrigerators and easily delivered to vulnerable groups, in exchange for very rare risks of blood clots that can have devastating neurological consequences even when they are not fatal.

The J&J vaccine has been shown to be 66% effective in preventing moderate to severe symptoms of Covid-19, according to clinical trials conducted on nearly 40,000 adults in many countries around the world.

Although the relationship between the vaccine and these rare blood clots has not been proven, scientists consider it a "possible cause" for this phenomenon, which was also observed in some people who received the AstraZeneca vaccine.

The European Medicines Regulatory Authority said Tuesday that blood clots should be included as a "very rare" side effect of the Johnson & Johnson vaccine, whose benefits remain greater than its risks.

The European Medicines Regulatory Authority said it had found a "possible link" between the vaccine and blood clotting, noting that its safety committee "concluded that a warning about the possibility of developing an abnormal blood clot with low blood platelets should be added to the information about the product."

Follow our latest local and sports news, and the latest political and economic developments via Google news